Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer  

作　　者：Chao Zhang Yu-Hui Dai Shu-Feng Lian Liang Liu Ting Zhao Jun-Ye Wen 

机构地区：[1]Department of Interventional Therapy,Hebei North University Affiliated First Hospital,Zhangjiakou 075000,Hebei Province,China [2]Zhangjiakou Qiaoxi District Maternal and Child Health Care Hospital,Zhangjiakou 075000,Hebei Province,China [3]Department of Hepatobiliary Surgery,Hebei People’s Hospital,Shijiazhuang 050055,Hebei Province,China

出　　处：《World Journal of Clinical Cases》2022年第27期9650-9656,共7页世界临床病例杂志

基　　金：Supported by Zhangjiakou Science and Technology Research and Development Program,No.1821154H;Zhangjiakou Technology Innovation Guidance Program,No.2021194H。

摘　　要：BACKGROUND Drug-eluting beads show good safety and promising efficacy when used as part of a transarterial chemoembolization regimen for primary liver cancer.However,data on the clinical efficacy and safety of pirarubicin-loaded beads combined with lobaplatin are lacking in China.AIM To evaluate the efficacy and safety of transcatheter arterial chemoembolization using pirarubicin-loaded beads combined with lobaplatin for primary liver cancer.METHODS Between January 2019 and March 2020,60 patients with primary liver cancer were selected at Hebei North University Affiliated First Hospital.According to different treatment methods,the participants were categorized into two groups with 30 patients treated with pirarubicin-loaded microspheres combined with lobaplatin included in an observation group and 30 patients treated with pirarubicin emulsion with lipiodol combined with lobaplatin were included in a control group.The progression-free survival,overall survival,clinical response rate,disease control rate,liver and kidney function and adverse reactions were compared between the two groups.RESULTS The progression-free survival was 14 mo in the observation group,which was significantly higher than 9 mo of the control group(P<0.05).The 6-mo,12-mo and 18-mo survival rates were 93.33%(28/30),66.67%(20/30)and 23.33%(7/30),respectively in the observation group,which were significantly higher than 83.33%(25/30),50.00%(15/30)and 13.33%(4/30),respectively,of the control group(all P<0.05).The clinical efficacy rate and disease control rate were 73.33%and 93.33%,respectively,in the observation group,which were significantly higher than those of the control group(53.55%and 80.00%,respectively,all P<0.05).There was no significant difference in alpha-fetoprotein between the two groups before the treatment(P>0.05).After the treatment,alpha-fetoprotein was 289.06±76.21 ng/m L in the observation group and 365.01±73.11 ng/m L in the control group,which were low in both groups compared with those before the treatment(all P<0.05).The

关 键 词：PIRARUBICIN Drug-loaded microspheres LOBAPLATIN Transcatheter arterial chemoembolization Primary liver cancer 

分 类 号：R735.7[医药卫生—肿瘤]